Crossject: praised for extended agreement on Zepizure
Thanks to this extension, the contract now covers a total of 11 European countries. As a reminder, Crossject will receive milestone payments of up to one million euros, as soon as marketing authorizations are obtained in the territories concerned.
Crossject will sell Zepizure to its partner with a coefficient corresponding to a share of the gross margin. The company covers the costs of regulatory development and holds potential marketing authorizations.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction